Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
84 hedge funds and large institutions have $472M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
15% more funds holding
Funds holding: 73 → 84 (+11)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
4% less capital invested
Capital invested by funds: $493M → $472M (-$20.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.46M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.1M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.68M |
| 5 |
Millennium Management
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$7.06M |
| 2 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$4.53M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$4.25M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.92M |
| 5 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$1.3M |
KNTE Hedge Fund Activity: Q3 2022 in Review
84 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2022, worth a combined $472M — down 4.1% from $493M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KNTE positions and 5 closed out — a net gain of 11 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $15.9M. The largest seller was Vida Ventures Advisors, cutting an estimated $7.06M.
- 84 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2022, up from 73 in Q2 2022.
- Funds reported $472M of Kinnate Biopharma Inc. Common Stock stock for Q3 2022, down 4.1% quarter-over-quarter.
- 16 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2022 and 5 closed out, a net change of +11 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2022 was Avidity Partners Management, an estimated $15.9M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2022 was Vida Ventures Advisors, an estimated $7.06M sold.
Based on aggregated 13F filings for Q3 2022.